SK285332B6 - Použitie pentózan polysulfátu na prípravu farmaceutického prostriedku na prevenciu alebo zníženie rozvoja nefrotoxicity alebo renálnej dysfunkcie a farmaceutický prostriedok - Google Patents

Použitie pentózan polysulfátu na prípravu farmaceutického prostriedku na prevenciu alebo zníženie rozvoja nefrotoxicity alebo renálnej dysfunkcie a farmaceutický prostriedok Download PDF

Info

Publication number
SK285332B6
SK285332B6 SK467-2000A SK4672000A SK285332B6 SK 285332 B6 SK285332 B6 SK 285332B6 SK 4672000 A SK4672000 A SK 4672000A SK 285332 B6 SK285332 B6 SK 285332B6
Authority
SK
Slovakia
Prior art keywords
pps
cyclosporin
pharmaceutical composition
pharmaceutically acceptable
composition
Prior art date
Application number
SK467-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK4672000A3 (en
Inventor
Gary E. Striker
Lilliane Striker
Kenneth H. Kortright
Original Assignee
Baker Norton Pharmaceuticals, Inc.
The United States Of America, Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharmaceuticals, Inc., The United States Of America, Represented By The Secretary filed Critical Baker Norton Pharmaceuticals, Inc.
Publication of SK4672000A3 publication Critical patent/SK4672000A3/sk
Publication of SK285332B6 publication Critical patent/SK285332B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
SK467-2000A 1997-10-09 1998-10-09 Použitie pentózan polysulfátu na prípravu farmaceutického prostriedku na prevenciu alebo zníženie rozvoja nefrotoxicity alebo renálnej dysfunkcie a farmaceutický prostriedok SK285332B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6294797P 1997-10-09 1997-10-09
PCT/US1998/021313 WO1999018961A1 (en) 1997-10-09 1998-10-09 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus

Publications (2)

Publication Number Publication Date
SK4672000A3 SK4672000A3 (en) 2001-09-11
SK285332B6 true SK285332B6 (sk) 2006-11-03

Family

ID=22045901

Family Applications (1)

Application Number Title Priority Date Filing Date
SK467-2000A SK285332B6 (sk) 1997-10-09 1998-10-09 Použitie pentózan polysulfátu na prípravu farmaceutického prostriedku na prevenciu alebo zníženie rozvoja nefrotoxicity alebo renálnej dysfunkcie a farmaceutický prostriedok

Country Status (23)

Country Link
US (1) US6187745B1 (da)
EP (1) EP1027053B1 (da)
JP (1) JP2001519392A (da)
KR (1) KR100515196B1 (da)
CN (1) CN1154492C (da)
AT (1) ATE269098T1 (da)
AU (1) AU748495B2 (da)
BR (1) BR9813860A (da)
CA (1) CA2304374A1 (da)
CZ (1) CZ297440B6 (da)
DE (1) DE69824619T2 (da)
DK (1) DK1027053T3 (da)
ES (1) ES2221714T3 (da)
HU (1) HUP0003904A3 (da)
IL (1) IL135235A0 (da)
NO (1) NO20001828L (da)
NZ (1) NZ503493A (da)
PL (1) PL191993B1 (da)
PT (1) PT1027053E (da)
RU (1) RU2191020C2 (da)
SK (1) SK285332B6 (da)
UA (1) UA65587C2 (da)
WO (1) WO1999018961A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001230994A1 (en) * 2000-01-19 2001-07-31 The United States of America, represented by The Secretary, Department of Health & Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP2116228A1 (en) * 2001-10-19 2009-11-11 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
PL372902A1 (en) * 2002-04-16 2005-08-08 Astellas Pharma Inc. New use
PL1748781T3 (pl) 2004-05-27 2013-05-31 Baxter Int Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów
AU2009284393B2 (en) 2008-08-22 2014-09-25 Takeda Pharmaceutical Company Limited Methods for treating bleeding disorders
US8632991B2 (en) 2010-01-14 2014-01-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
US8871741B2 (en) * 2010-01-15 2014-10-28 Icahn School Of Medicine At Mount Sinai Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
EP3417865A1 (en) 2011-07-19 2018-12-26 Baxalta GmbH Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
WO2013052380A2 (en) * 2011-10-05 2013-04-11 Allergan, Inc. Compositions for enhancing nail health
US9417251B2 (en) 2012-08-14 2016-08-16 Baxalta GmbH Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
RU2680098C1 (ru) * 2015-06-12 2019-02-15 Вишал Джаджодиа Свати Лекарственное средство, содержащее пентозанполисульфат натрия, для использования в лечении обструкции выходного отверстия мочевого пузыря и/или симптомов нижних мочевых путей

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843241A1 (de) * 1988-12-22 1990-06-28 Skrezek Christian Nephroprotektive infusionsloesung
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
GB9116836D0 (en) * 1991-08-05 1991-09-18 Sandoz Ltd Organic compounds
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
RU2027471C1 (ru) * 1992-04-14 1995-01-27 Северо-Кавказский горно-металлургический институт Способ очистки суспензий и вибрационный фильтр-сгуститель для его осуществления
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) * 1995-02-03 1996-08-13 L T T Kenkyusho:Kk 腎不全治療剤
US5643892A (en) 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
KR100515196B1 (ko) 2005-09-16
EP1027053B1 (en) 2004-06-16
ATE269098T1 (de) 2004-07-15
CN1154492C (zh) 2004-06-23
BR9813860A (pt) 2001-03-20
ES2221714T3 (es) 2005-01-01
HUP0003904A1 (hu) 2001-08-28
KR20010030749A (ko) 2001-04-16
NO20001828D0 (no) 2000-04-07
CN1275080A (zh) 2000-11-29
RU2191020C2 (ru) 2002-10-20
NZ503493A (en) 2001-11-30
PT1027053E (pt) 2004-09-30
US6187745B1 (en) 2001-02-13
WO1999018961A1 (en) 1999-04-22
CZ297440B6 (cs) 2006-12-13
SK4672000A3 (en) 2001-09-11
DK1027053T3 (da) 2004-09-06
EP1027053A4 (en) 2002-05-22
CZ20001274A3 (cs) 2001-12-12
HK1026845A1 (en) 2000-12-29
PL339774A1 (en) 2001-01-02
JP2001519392A (ja) 2001-10-23
UA65587C2 (en) 2004-04-15
DE69824619T2 (de) 2005-06-23
IL135235A0 (en) 2001-05-20
CA2304374A1 (en) 1999-04-22
EP1027053A1 (en) 2000-08-16
NO20001828L (no) 2000-05-15
HUP0003904A3 (en) 2006-06-28
PL191993B1 (pl) 2006-08-31
DE69824619D1 (de) 2004-07-22
AU748495B2 (en) 2002-06-06
AU9794398A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
SK4672000A3 (en) Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
CA2730603A1 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2016172745A (ja) ペプチドの組成物及びその調製方法
CA2726913A1 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2018202986A1 (en) ANG-(1-7) derivative oligopeptides and methods for using and producing the same
Jin et al. C-type natriuretic peptide ameliorates ischemia/reperfusion-induced acute kidney injury by inhibiting apoptosis and oxidative stress in rats
RU2462262C2 (ru) Неиммуносупрессорный циклоспорин для лечения врожденной миопатии ульриха
KR20010043969A (ko) 염증성 자기면역 질환의 치료에서 사이클로스포린의 용도
EP0835106A1 (en) Method of treating renal disease using an ace inhibitor and an aii antagonist
KR101737656B1 (ko) 당뇨병의 예방을 위한 설폰아마이드
Bennett Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs
Pally et al. Tolerability profile of sodium mycophenolate (ERL080) and mycophenolate mofetil with and without cyclosporine (Neoral) in the rat
JPH08231390A (ja) カルニチン類を含む医薬組成物
US6355639B1 (en) Reverse prenyl compounds as immunosuppressants
MXPA00003194A (en) Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
HK1026845B (en) Method of preventing nephrotoxicity caused by cyclosporins or tacrolimus
HUP0300686A2 (hu) Szívtranszplantátumok kilökődésének kezelésére szolgáló gyógyszerkészítmény, mely nem-peptid CCR1 receptor antagonista és ciklosporin A kombinációját tartalmazza
EP1817016A2 (en) Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
EA012982B1 (ru) Стабилизированная фармацевтическая композиция лейкотриен в(ltb) агента
CN116889615A (zh) 一种降血压的药物组合及其应用
CA2557625A1 (en) Method of treatment of systemic injury secondary to burns
WO2011141891A1 (en) Use of cycloundecadepsipeptide compounds
WO2010043444A2 (en) Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
AU2004241673A1 (en) Method of treatment of systemic injury secondary to burns
HK1148665B (en) Non-immunosuppressive cyclosporin for the treatment of muscular dystrophy